Allogene Therapeutics (ALLO)

• Market cap: $315M
• 1 day: 3.57%
• 5 days: 5.84%
• 1 month: -21.62%
• 3 months: -20.33%
• 6 months: -46.10%
• Year to date: -34.09%
• 1 year: -58.69%
• 5 years: -94.75%
• 10 years: -94.20%
• Sector: Healthcare
• Industry: Biotechnology

About: Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Employees: 361

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

153% more call options, than puts

Call options by funds: $446K | Put options by funds: $176K

121% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 14

48% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 42

33% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 4 (+1) [Q4]

11.26% more ownership

Funds ownership: 78.61% [Q3] → 89.87% (+11.26%) [Q4]

11% more funds holding

Funds holding: 155 [Q3] → 172 (+17) [Q4]

13% less capital invested

Capital invested by funds: $460M [Q3] → $401M (-$59M) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $5 245% upside
• Avg. target: $9.25 538% upside
• High target: $14 866% upside

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Robert Burns 16% 1-year accuracy 28 / 172 met price target	452% upside $8	Buy Maintained	19 Mar 2025
Canaccord Genuity John Newman 12% 1-year accuracy 3 / 26 met price target	866% upside $14	Buy Maintained	14 Mar 2025
RBC Capital Luca Issi 7% 1-year accuracy 4 / 55 met price target	590% upside $10	Outperform Reiterated	14 Mar 2025
Citizens Capital Markets Reni Benjamin 15% 1-year accuracy 6 / 40 met price target	245% upside $5	Market Outperform Upgraded	14 Mar 2025